Innovative Solutions Optimize the Harvest Process
in Gene Therapy Manufacturing Sustainably and at Scale
RADNOR,
Pa., July 1, 2024 /PRNewswire/ -- Avantor, Inc.
(NYSE: AVTR), a leading global provider of mission-critical
products and services to customers in the life sciences and
advanced technologies industries, today announced the launch
of two innovative products that together sustainably optimize the
gene therapy harvest process: J.T.Baker® Cell Lysis
Solution and J.T.Baker® Endonuclease.
"These products help gene therapy manufacturers improve harvest
while preserving the quality and integrity of highly valuable viral
particles," said Benoit Gourdier,
Executive Vice President of Bioscience Production at Avantor.
"These products also respond to growing demand from
biopharmaceutical customers for environmentally sustainable
options."
Avantor scientists developed J.T.Baker® Cell Lysis
Solution as a safe and effective alternative to Octoxynol-9, which
is on the European Chemicals Agency's "substance of very high
concern" list under REACH regulations given concerns that it is
toxic to aquatic life when entering the environment through waste
systems.
J.T.Baker® Cell Lysis Solution is biodegradable and
exhibits low ecotoxicity when used in the upstream harvesting
process to release adeno-associated virus (AAV) from host cells, a
pivotal step in gene therapy workflows. Avantor®
studies1 show that the solution improves the efficiency
of viral vector release across a range of cell densities and
temperatures while protecting the viral particles from damage
during processing.
As a ready-to-use reagent that does not require refrigeration or
advanced preparation, the J.T.Baker® Cell Lysis Solution
streamlines the harvest process and minimizes contamination risk by
eliminating the need for pre-dilution and filtration, significantly
reducing bioburden risk. The solution's high-concentration
formulation also lowers viscosity and foam generation to reclaim
valuable bioreactor space.
Pairing J.T.Baker® Cell Lysis Solution with
compatible J.T.Baker® Endonuclease — an enzyme that
removes remaining impurities — can further reduce the number of
steps at harvest, enabling a more efficient process. Working
together to provide robust DNA clearance and reduced aggregation,
these solutions can be customized for any scale with a wide range
of cGMP grade size options.
Avantor's J.T.Baker® Cell Lysis Solution and
J.T.Baker® Endonuclease are part of a full range of
modular and scalable chemical and fluid handling solutions. For
additional product information, please visit our web site.
About Avantor
Avantor® is a leading life
science tools company and global provider of mission-critical
products and services to the life sciences and advanced technology
industries. We work side-by-side with customers at every step of
the scientific journey to enable breakthroughs in medicine,
healthcare, and technology. Our portfolio is used in virtually
every stage of the most important research, development and
production activities at more than 300,000 customer locations in
180 countries. For more information, visit avantorsciences.com and
find us on LinkedIn, X (Twitter) and Facebook.
Global Media Contact
Emily Collins
Vice President, External Communications
Avantor
332-239-3910
Emily.Collins@avantorsciences.com
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
1 Novel Cell Lysis Solution: Scaling up the
harvest process while preserving what matters,
Kroeger-Fahnestock, 2024
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avantor-announces-new-jtbaker-cell-lysis-solution-and-jtbaker-endonuclease-302186455.html
SOURCE Avantor and Financial News